June 01, 2026 —
Voyager Therapeutics announced that the U.S. FDA has cleared its Investigational New Drug application for VY1706, an investigational AAV gene therapy designed to reduce tau in adults with early Alzheimer’s disease. The clearance enables Voyager to initiate a clinical trial, with dosing expected to begin in the second half of 2026.
VY1706 is designed as a one-time intravenous therapy targeting MAPT mRNA, the transcript that encodes tau. The therapy uses a vectorized siRNA payload intended to lower both intracellular and extracellular tau in the brain. Tau pathology is strongly associated with neurodegeneration and cognitive decline in Alzheimer’s disease, making it an important target for disease-modifying therapeutic development.
A key feature of VY1706 is its delivery system. The siRNA payload is packaged in Voyager’s TRACER™ AAV capsid, which leverages ALPL, a conserved receptor identified by Voyager, to support brain delivery after intravenous administration. This approach is designed to enable broad central nervous system distribution through a single systemic dose while reducing liver exposure, a known safety concern for some systemically delivered gene therapies.
The planned clinical trial will be a multi-site, open-label, dose-escalation study enrolling up to 18 adults with early Alzheimer’s disease who have evidence of tau pathology confirmed by PET imaging. Participants will receive a one-time IV dose of VY1706 across three dose cohorts, with the highest dose not exceeding 5E13 vg/kg, the top dose evaluated in GLP toxicology studies. The primary endpoint will assess safety and tolerability, while secondary endpoints will evaluate effects on tau biology, including CSF tau biomarkers and tau PET imaging.
The IND clearance is supported by a comprehensive preclinical program across multiple species. In non-human primates, three-month GLP toxicology data showed a favorable tolerability profile, with no adverse clinical pathology or histopathological findings up to 5E13 vg/kg at 13 weeks after a single IV dose. VY1706 produced dose-dependent reductions of up to 51–75% in MAPT mRNA and 48–64% in tau protein across Alzheimer’s-relevant brain regions, including the entorhinal cortex, frontal cortex, temporal cortex, and hippocampus.
Voyager has also reported that VY1706 reduced tau protein by up to 75% in key brain regions in preclinical studies and demonstrated liver detargeting. The company describes the IND clearance as the first for a tau-targeted gene therapy.
If successfully translated, VY1706 could represent a new therapeutic direction in Alzheimer’s disease: durable tau reduction through a one-time, IV-administered AAV gene therapy. While clinical validation is still needed, the program highlights the growing role of engineered capsids, CNS-directed delivery, and vectorized RNA interference in the development of next-generation treatments for neurodegenerative disease.
